Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E26.51 EPS (ttm)0.93 Insider Own1.30% Shs Outstand305.39M Perf Week0.37%
Market Cap7.58B Forward P/E27.58 EPS next Y0.90 Insider Trans-31.67% Shs Float297.40M Perf Month-5.20%
Income293.80M PEG0.58 EPS next Q0.12 Inst Own82.50% Short Float5.53% Perf Quarter32.92%
Sales979.20M P/S7.74 EPS this Y-53.80% Inst Trans3.30% Short Ratio4.06 Perf Half Y48.41%
Book/sh5.72 P/B4.32 EPS next Y102.26% ROA16.20% Target Price26.69 Perf Year23.67%
Cash/sh3.11 P/C7.94 EPS next 5Y46.00% ROE18.00% 52W Range13.67 - 27.80 Perf YTD40.24%
Dividend- P/FCF18.58 EPS past 5Y22.50% ROI17.30% 52W High-11.12% Beta1.52
Dividend %- Quick Ratio8.00 Sales past 5Y107.60% Gross Margin96.40% 52W Low80.76% ATR1.14
Employees617 Current Ratio8.10 Sales Q/Q5.30% Oper. Margin34.50% RSI (14)53.40 Volatility3.83% 4.48%
OptionableYes Debt/Eq0.00 EPS Q/Q-36.10% Profit Margin30.00% Rel Volume0.70 Prev Close24.33
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout0.00% Avg Volume4.06M Price24.71
Recom2.00 SMA20-2.41% SMA5013.57% SMA20029.61% Volume2,850,753 Change1.56%
Mar-04-20Initiated Barclays Overweight $26
Jan-13-20Initiated SunTrust Buy $31
Nov-13-19Initiated BofA/Merrill Buy $22
Mar-18-19Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-17-18Initiated Goldman Neutral $22
Sep-10-18Initiated Morgan Stanley Underweight $19
May-11-18Reiterated Needham Buy $33 → $30
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Sep-12-17Reiterated Needham Buy $28 → $30
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
May-28-20 06:58AM  Is There An Opportunity With Exelixis, Inc.'s (NASDAQ:EXEL) 49% Undervaluation? Simply Wall St.
May-25-20 09:36PM  Edited Transcript of EXEL earnings conference call or presentation 5-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-20-20 01:30PM  3 Charts That Suggest Biotech Stocks Are Headed Higher Investopedia
May-13-20 05:00PM  Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types Business Wire
09:54AM  Better Buy: bluebird bio vs. Exelixis Motley Fool
May-06-20 04:05PM  Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May Business Wire
11:40AM  Exelixis (EXEL) Q1 Earnings and Revenues Surpass Estimates Zacks
01:01AM  Exelixis Inc (EXEL) Q1 2020 Earnings Call Transcript Motley Fool
May-05-20 06:25PM  Exelixis (EXEL) Q1 Earnings and Revenues Beat Estimates Zacks
04:05PM  Exelixis Announces First Quarter 2020 Financial Results and Provides Corporate Update Business Wire
03:00PM  Exelixis, Inc. to Host Earnings Call ACCESSWIRE
May-01-20 01:14PM  Exelixis Charts Are Pointed Higher, Look to Buy a Dip TheStreet.com
Apr-28-20 12:33PM  Earnings Preview: Exelixis (EXEL) Q1 Earnings Expected to Decline Zacks
Apr-22-20 10:30AM  Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More Zacks
09:00AM  How Does Exelixis's (NASDAQ:EXEL) P/E Compare To Its Industry, After Its Big Share Price Gain? Simply Wall St.
Apr-21-20 04:05PM  Exelixis to Release First Quarter 2020 Financial Results on Tuesday, May 5, 2020 Business Wire
12:59PM  Company News for Apr 21, 2020 Zacks
12:43PM  Exelixis Stock Strength Jumps On Positive Cancer Treatment Results Investor's Business Daily
Apr-20-20 06:01PM  How this East Bay biotech pushed past the 'negativity' with a big boost to its kidney cancer drug American City Business Journals +21.27%
04:19PM  This Biotech Stock Just Blew Into A Profit-Taking Zone Here's Why Investor's Business Daily
11:03AM  Kidney Cancer Drug From Bristol-Myers and Exelixis Meets Key Phase III Endpoint TheStreet.com
07:12AM  Exelixis, Bristol-Myers stocks get a boost from upbeat trial results of a Kidney cancer treatment MarketWatch
06:59AM  CORRECTED-Bristol Myers says Opdivo performs well in kidney, lung cancer trials Reuters
06:59AM  Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Previously Untreated Advanced Renal Cell Carcinoma Business Wire
Apr-09-20 11:40AM  EXEL vs. ILMN: Which Stock Should Value Investors Buy Now? Zacks
Apr-08-20 04:05PM  Exelixis to Webcast Virtual Fireside Chat as Part of the Needham Healthcare Conference on April 15, 2020 Business Wire +5.79%
Mar-26-20 03:41PM  Were These Hedge Funds Right About Selling Exelixis, Inc. (EXEL)? Insider Monkey +9.58%
11:30AM  Why Is Exelixis (EXEL) Down 15.6% Since Last Earnings Report? Zacks
Mar-25-20 03:01AM  Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Cell Carcinoma Business Wire
Mar-24-20 11:40AM  EXEL vs. ILMN: Which Stock Should Value Investors Buy Now? Zacks
Mar-17-20 07:02AM  A Sliding Share Price Has Us Looking At Exelixis, Inc.'s (NASDAQ:EXEL) P/E Ratio Simply Wall St.
Mar-02-20 04:05PM  Exelixis Announces George A. Scangos, Ph.D. to Retire From Its Board of Directors Business Wire
Feb-27-20 06:19AM  Exelixis, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next Simply Wall St.
12:31AM  Edited Transcript of EXEL earnings conference call or presentation 25-Feb-20 10:00pm GMT Thomson Reuters StreetEvents
Feb-26-20 04:05PM  Exelixis Announces Webcasts of Investor Conference Presentations in March Business Wire
10:03AM  Exelixis (EXEL) Beats on Earnings, Misses on Sales in Q4 Zacks
Feb-25-20 06:35PM  Exelixis (EXEL) Tops Q4 Earnings Estimates Zacks
04:06PM  Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Relapsed Radioiodine-Refractory Differentiated Thyroid Cancer Business Wire
04:05PM  Exelixis Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update Business Wire
Feb-21-20 11:30AM  Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-19-20 07:28AM  The Exelixis (NASDAQ:EXEL) Share Price Has Soared 689%, Delighting Many Shareholders Simply Wall St.
Feb-12-20 04:05PM  Exelixis to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 25, 2020 Business Wire
02:10PM  3 Mid-Cap Growth Stocks to Buy InvestorPlace
Feb-11-20 05:50PM  Exelixis (EXEL) Outpaces Stock Market Gains: What You Should Know Zacks
07:23AM  The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga
Feb-10-20 05:00PM  Exelixis Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Business Wire
Feb-04-20 05:50PM  Exelixis (EXEL) Gains But Lags Market: What You Should Know Zacks
Jan-29-20 08:30AM  The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut Benzinga
02:01AM  Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX® (cabozantinib) for Advanced Hepatocellular Carcinoma Business Wire
Jan-28-20 09:52AM  How Alameda again became a biotech hotspot American City Business Journals
Jan-27-20 08:07AM  Roche Submits Application for Tecentriq-Avastin Combo in HCC Zacks
Jan-24-20 07:30AM  Exelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular Carcinoma Business Wire -7.92%
Jan-21-20 06:10PM  How this East Bay biotech went from debt to expansion American City Business Journals
Jan-17-20 11:40AM  GILD or EXEL: Which Is the Better Value Stock Right Now? Zacks
Jan-14-20 07:38AM  Does Exelixis, Inc. (NASDAQ:EXEL) Have A Good P/E Ratio? Simply Wall St. +6.39%
Jan-13-20 12:10PM  Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? Zacks
Jan-12-20 04:00PM  Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance Business Wire
Jan-09-20 04:39PM  2019 Review: Top Hedge Fund Stocks vs. Exelixis, Inc. (EXEL) Insider Monkey
Jan-08-20 10:13AM  Exelixis to Expand Prostate Cancer Cohort of Cabometyx Study Zacks
10:07AM  Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data Zacks
Jan-07-20 04:05PM  Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020 Business Wire +6.38%
07:30AM  Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors Business Wire
Dec-19-19 07:00AM  Exelixis Enters into a Clinical Collaboration for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors Business Wire
Dec-13-19 08:22AM  Roche's (RHHBY) Tecentriq Combo Succeeds in Melanoma Study Zacks
08:10AM  The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer Benzinga
01:02AM  Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma Business Wire
Dec-06-19 01:03PM  Hedge Funds Are Warming Up To Exelixis, Inc. (EXEL) Insider Monkey
Dec-05-19 04:56AM  How Should Investors React To Exelixis, Inc.'s (NASDAQ:EXEL) CEO Pay? Simply Wall St.
Nov-26-19 04:06PM  Exelixis Announces Webcasts of Investor Conference Presentations in December Business Wire
12:20PM  Why Did Farallon Capital Get Out of These 3 Biotech Stocks? TipRanks
Nov-12-19 04:05PM  Exelixis to Present at the Stifel 2019 Healthcare Conference on November 19, 2019 Business Wire
08:02AM  Exelixis Partner Ipsen Announces Health Canadas Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma Business Wire
Nov-07-19 08:01PM  Exelixis Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy Business Wire
Nov-05-19 03:36AM  Edited Transcript of EXEL earnings conference call or presentation 30-Oct-19 9:00pm GMT Thomson Reuters StreetEvents
Oct-31-19 11:45AM  Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales Zacks -11.10%
Oct-30-19 06:45PM  Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates Zacks
04:05PM  Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update Business Wire
08:00AM  Is There An Opportunity With Exelixis, Inc.'s (NASDAQ:EXEL) 31% Undervaluation? Simply Wall St.
Oct-29-19 10:40AM  Exelixis (EXEL) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-25-19 10:15AM  Is Exelixis, Inc. (EXEL) Going To Burn These Hedge Funds ? Insider Monkey
Oct-23-19 10:33AM  Earnings Preview: Exelixis (EXEL) Q3 Earnings Expected to Decline Zacks
Oct-16-19 04:05PM  Exelixis to Release Third Quarter 2019 Financial Results on Wednesday, October 30, 2019 Business Wire
Oct-14-19 12:08PM  7 Under-The-Radar Growth Stocks That Could Benefit New Investors InvestorPlace
Oct-07-19 11:58AM  What Kind Of Shareholders Own Exelixis, Inc. (NASDAQ:EXEL)? Simply Wall St.
09:54AM  Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study Zacks
Oct-01-19 11:45AM  Seattle Genetics Up on Positive Data From Bladder Cancer Study Zacks
Sep-25-19 04:05PM  Exelixis to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019 Business Wire
Sep-23-19 10:27AM  Pfizer's Bavencio Gets CHMP Recommendation for First-Line RCC Zacks
Sep-20-19 05:48PM  3 Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices GuruFocus.com
Sep-16-19 08:20AM  Have Insiders Been Selling Exelixis, Inc. (NASDAQ:EXEL) Shares? Simply Wall St.
Sep-13-19 09:36AM  Renal Cell Carcinoma Space in Focus: Some Key Developments Zacks
Sep-04-19 10:17AM  Biotech vet George Scangos steers new company toward nine-figure IPO American City Business Journals
Sep-03-19 04:05PM  Exelixis to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 Business Wire
Aug-26-19 08:04AM  These Fundamentals Make Exelixis, Inc. (NASDAQ:EXEL) Truly Worth Looking At Simply Wall St.
Aug-21-19 12:55PM  10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar InvestorPlace
Aug-20-19 11:15PM  Exelixis Inc (EXEL) EVP and General Counsel Jeffrey Hessekiel Sold $1.6 million of Shares GuruFocus.com
10:09AM  Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales Zacks
Aug-16-19 09:15PM  Exelixis Inc (EXEL) President and CEO Michael Morrissey Sold $704,654 of Shares GuruFocus.com +8.93%
Aug-05-19 11:46PM  Edited Transcript of EXEL earnings conference call or presentation 31-Jul-19 9:00pm GMT Thomson Reuters StreetEvents
10:00AM  Exelixis Hits Blockbuster Status Motley Fool
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, and other kinases implicated in growth and spread of cancer. It has collaboration and license agreement with Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., Roche, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Garber Alan MDirectorMay 22Sale24.4236,111881,83112,718May 22 08:53 PM
MARCHESI VINCENT TDirectorMay 21Option Exercise5.8240,000232,800130,212May 22 09:11 PM
MARCHESI VINCENT TDirectorMay 21Sale24.6440,000985,60090,212May 22 09:11 PM
Haley Patrick J.EVP, CommercialMay 20Sale24.993,15178,743115,340May 22 08:17 PM
WILLSEY LANCEDirectorMay 18Option Exercise4.5830,000137,400398,273May 20 08:36 PM
SCANGOS GEORGE ADirectorMay 18Sale25.9675,0001,947,000714,717May 20 08:35 PM
WILLSEY LANCEDirectorMay 18Sale26.2630,000787,800368,273May 20 08:36 PM
SCANGOS GEORGE ADirectorMay 15Option Exercise5.1051,686263,613789,717May 15 08:31 PM
MORRISSEY MICHAELPresident and CEOMay 15Option Exercise6.21100,000621,000185,985May 15 09:29 PM
WILLSEY LANCEDirectorMay 14Option Exercise5.9215,00088,800383,273May 15 08:19 PM
WILLSEY LANCEDirectorMay 14Sale25.2615,000378,900368,273May 15 08:19 PM
Hessekiel JeffreyEVP and General CounselMay 13Option Exercise1.7025,00042,500264,188May 15 08:20 PM
PAPADOPOULOS STELIOSDirectorMay 13Option Exercise5.82120,791703,0041,173,359May 15 08:18 PM
Hessekiel JeffreyEVP and General CounselMay 11Option Exercise1.9038,00672,211277,194May 11 08:36 PM
MARCHESI VINCENT TDirectorMay 11Option Exercise4.5830,000137,400112,484May 13 09:16 PM
Hessekiel JeffreyEVP and General CounselMay 11Sale27.0938,0061,029,583239,188May 11 08:36 PM
MARCHESI VINCENT TDirectorMay 11Sale26.3030,000789,00082,484May 13 09:16 PM
Haley Patrick J.EVP, CommercialMay 08Option Exercise1.7621,37537,620139,866May 08 09:16 PM
PAPADOPOULOS STELIOSDirectorMay 08Option Exercise5.0345,000226,2001,097,568May 08 09:18 PM
Senner Christopher J.EVP and CFOMay 08Option Exercise3.6678,583287,614199,286May 08 09:22 PM
Hessekiel JeffreyEVP and General CounselMay 08Option Exercise1.9025,00047,500264,188May 11 08:36 PM
Hessekiel JeffreyEVP and General CounselMay 08Sale26.0425,000651,000239,188May 11 08:36 PM
Senner Christopher J.EVP and CFOMay 08Sale25.8178,5832,028,227120,703May 08 09:22 PM
Haley Patrick J.EVP, CommercialMay 08Sale25.8721,375552,971118,491May 08 09:16 PM
PAPADOPOULOS STELIOSDirectorMay 08Sale25.8445,0001,162,8001,052,568May 08 09:18 PM
Lamb PeterEVP, Scientific Strategy & CSOMay 07Option Exercise5.5150,000275,500176,531May 08 09:11 PM
POSTE GEORGEDirectorMay 07Option Exercise5.8230,000174,600142,792May 08 09:13 PM
FELDBAUM CARL BDirectorMay 07Option Exercise4.2731,546134,79840,067May 08 09:14 PM
Senner Christopher J.EVP and CFOMay 07Option Exercise3.6621,41778,386142,120May 08 09:22 PM
Hessekiel JeffreyEVP and General CounselMay 07Option Exercise1.9030,00057,000269,188May 11 08:36 PM
Hessekiel JeffreyEVP and General CounselMay 07Sale25.6130,000768,300239,188May 11 08:36 PM
Senner Christopher J.EVP and CFOMay 07Sale25.8021,417552,559120,703May 08 09:22 PM
FELDBAUM CARL BDirectorMay 07Sale25.0231,546789,2818,521May 08 09:14 PM
POSTE GEORGEDirectorMay 07Sale25.6130,000768,300112,792May 08 09:13 PM
Lamb PeterEVP, Scientific Strategy & CSOMay 07Sale25.5450,0001,277,000126,531May 08 09:11 PM
MORRISSEY MICHAELPresident and CEOMay 06Option Exercise1.70285,284484,983371,269May 08 09:10 PM
MORRISSEY MICHAELPresident and CEOApr 27Option Exercise1.70285,000484,500370,985Apr 29 08:10 PM
SCANGOS GEORGE ADirectorApr 24Sale26.2415,000393,600738,031Apr 24 08:24 PM
Haley Patrick J.EVP, CommercialApr 23Option Exercise1.705,0008,500121,873Apr 24 08:22 PM
MORRISSEY MICHAELPresident and CEOApr 23Option Exercise5.51250,0001,377,500335,985Apr 24 08:41 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 23Option Exercise1.70100,000170,000425,122Apr 24 08:25 PM
SCANGOS GEORGE ADirectorApr 23Sale25.99100,0002,598,635753,031Apr 24 08:24 PM
Haley Patrick J.EVP, CommercialApr 23Sale26.005,000130,000116,873Apr 24 08:22 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 23Sale26.00100,0002,600,000325,122Apr 24 08:25 PM
SCANGOS GEORGE ADirectorApr 22Sale25.054,200105,210853,031Apr 22 08:50 PM
MORRISSEY MICHAELPresident and CEOApr 21Option Exercise5.51220,0001,212,200393,064Apr 22 09:53 PM
SCANGOS GEORGE ADirectorApr 21Sale25.045,800145,232857,231Apr 22 08:50 PM
MORRISSEY MICHAELPresident and CEOApr 20Option Exercise5.51240,0001,322,400325,985Apr 22 09:53 PM
Haley Patrick J.EVP, CommercialApr 20Option Exercise1.705,0008,500121,873Apr 22 08:49 PM
SCANGOS GEORGE ADirectorApr 20Sale23.8950,0001,194,637863,031Apr 22 08:50 PM
Haley Patrick J.EVP, CommercialApr 20Sale24.005,000120,000116,873Apr 22 08:49 PM
SCANGOS GEORGE ADirectorApr 15Sale18.3125,000457,750913,031Apr 17 08:11 PM
SCANGOS GEORGE ADirectorApr 08Sale18.357,065129,643938,031Apr 09 08:20 PM
SCANGOS GEORGE ADirectorApr 07Sale18.2516,435299,939945,096Apr 09 08:20 PM
Lamb PeterEVP, Scientific Strategy & CSOApr 06Option Exercise5.5150,000275,500176,531Apr 08 08:12 PM
Lamb PeterEVP, Scientific Strategy & CSOApr 06Sale17.2650,000863,000126,531Apr 08 08:12 PM
WYSZOMIERSKI JACK LDirectorApr 03Option Exercise5.0345,000226,200175,526Apr 03 08:38 PM
WYSZOMIERSKI JACK LDirectorApr 03Sale16.5713,848229,461161,678Apr 03 08:38 PM
SCANGOS GEORGE ADirectorMar 31Sale18.061,50027,090961,531Apr 02 08:08 PM
Haley Patrick J.EVP, CommercialMar 20Sale15.374,31866,368116,873Mar 20 09:03 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOMar 04Option Exercise1.70100,000170,000425,122Mar 06 08:01 PM
MORRISSEY MICHAELPresident and CEOMar 04Option Exercise5.5150,000275,500135,985Mar 06 08:07 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOMar 04Sale19.40100,0001,940,000325,122Mar 06 08:01 PM
FELDBAUM CARL BDirectorMar 03Option Exercise5.6238,000213,72046,521Mar 05 08:00 PM
FELDBAUM CARL BDirectorMar 03Sale18.8438,000716,0138,521Mar 05 08:00 PM
COHEN CHARLESDirectorFeb 28Option Exercise5.0345,000226,20065,979Mar 02 09:14 PM
MORRISSEY MICHAELPresident and CEOFeb 26Option Exercise5.5125,000137,750110,985Feb 28 08:05 PM
MORRISSEY MICHAELPresident and CEOFeb 26Sale18.9125,000472,85085,985Feb 28 08:05 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 19Option Exercise5.5140,000220,400365,122Feb 21 08:00 PM
MORRISSEY MICHAELPresident and CEOFeb 19Option Exercise0.0025,0000110,985Feb 21 08:03 PM
Haley Patrick J.EVP, CommercialFeb 19Option Exercise0.005,0000126,191Feb 21 08:17 PM
Haley Patrick J.EVP, CommercialFeb 19Sale22.005,000110,000121,191Feb 21 08:17 PM
MORRISSEY MICHAELPresident and CEOFeb 19Sale21.7525,000543,75085,985Feb 21 08:03 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 19Sale21.5040,000860,000325,122Feb 21 08:00 PM
SCANGOS GEORGE ADirectorFeb 18Sale20.7350,0001,036,500963,031Feb 21 08:28 PM
Garber Alan MDirectorFeb 14Sale21.0212,500262,75048,829Feb 14 08:36 PM
MORRISSEY MICHAELPresident and CEOFeb 13Option Exercise5.5125,000137,750110,985Feb 14 08:48 PM
MORRISSEY MICHAELPresident and CEOFeb 13Sale20.1125,000502,75085,985Feb 14 08:48 PM
SCANGOS GEORGE ADirectorFeb 12Sale20.0221,000420,4201,013,031Feb 12 08:21 PM
SCANGOS GEORGE ADirectorFeb 11Sale20.144,00080,5601,034,031Feb 12 08:21 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 07Option Exercise5.5150,000275,500375,122Feb 07 08:43 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 07Sale18.3750,000918,500325,122Feb 07 08:43 PM
MORRISSEY MICHAELPresident and CEOJan 29Option Exercise5.5125,000137,750110,985Jan 31 08:03 PM
MORRISSEY MICHAELPresident and CEOJan 29Sale17.8725,000446,75085,985Jan 31 08:03 PM
MORRISSEY MICHAELPresident and CEOJan 23Option Exercise5.5125,000137,750110,985Jan 24 08:19 PM
MORRISSEY MICHAELPresident and CEOJan 23Sale19.4125,000485,25085,985Jan 24 08:19 PM
SCANGOS GEORGE ADirectorJan 22Sale19.7525,000493,7501,038,031Jan 24 08:17 PM
MORRISSEY MICHAELPresident and CEOJan 16Option Exercise5.5125,000137,750110,985Jan 17 08:45 PM
MORRISSEY MICHAELPresident and CEOJan 16Sale20.3325,000508,25085,985Jan 17 08:45 PM
SCANGOS GEORGE ADirectorJan 15Sale20.3925,000509,7501,063,031Jan 17 08:42 PM
MARCHESI VINCENT TDirectorJan 15Sale20.0161,6831,234,27782,484Jan 17 08:50 PM
MORRISSEY MICHAELPresident and CEOJan 08Option Exercise5.5125,000137,750110,985Jan 09 08:35 PM
MORRISSEY MICHAELPresident and CEOJan 08Sale18.8525,000471,25085,985Jan 09 08:35 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOJan 07Option Exercise5.5150,000275,500375,122Jan 09 08:27 PM
Garber Alan MDirectorJan 07Option Exercise5.3986,956468,884148,285Jan 09 08:31 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOJan 07Sale17.9650,000898,000325,122Jan 09 08:27 PM
Garber Alan MDirectorJan 07Sale18.0186,9561,566,07861,329Jan 09 08:31 PM
MORRISSEY MICHAELPresident and CEOJan 02Option Exercise5.5125,000137,750110,985Jan 03 07:46 PM
MORRISSEY MICHAELPresident and CEOJan 02Sale17.4925,000437,25085,985Jan 03 07:46 PM
SCANGOS GEORGE ADirectorDec 27Sale18.2525,000456,2501,090,531Dec 27 08:52 PM
open in yahoo | open in reuters | open in google